Resonance Health Ltd · ASX:RHT
Resonance Health — Shareholder Meeting (November 2023)
11 slides from Resonance Health's shareholder meeting presentation, Nov 16, 2023
Slide 1: AGM Presentation
AGM PRESENTATION For personal use only November 2023 Andrew Harrison, CEO 1
Slide 2: Our Business – Medical Devices
Our Business – Medical Devices Resonance has a large complex global footprint of imaging and clinical trial customers. For personal use only Customers • Diagnostic • Clinical Trials Core Products Snapshot • In 48 Countries • Over 400 Active Sites • 90,000 Analysis Completed • Over 35 clinical trials
Slide 3: Our Business – Clinical Trial Services
Our Business – Clinical Trial Services This trial represents a significant change in scale, an opportunity to expand service offerings, and generate greater revenues from within the clinical trial ecosystem. For personal use only ü Resonance was awarded the Sun Pharmaceutical Trial in August 2023. ü
Slide 4: Antisense Oligonucleotide
Our Business – Antisense Oligonucleotide ASON project represents an opportunity to develop a platform business based on Cyclophilin (A,B,D) inhibition across organ types, diseases, and in combination with other therapies. For personal use only ü Using ASO’s as a method of treating disease is becomin
Slide 5: Operating Performance
Our Business – Operating Performance For personal use only Jul-Sept 23* FY2023 § Revenue up significantly year on year. Revenue $2.17M (+107% pcp) $4.51m § Expected to continue through second half. Operating EBITDA § EBITDA significantly up year on year. $0.6m -$0.80m (ex share-based payments) § Str
Slide 6: Growth - Existing Business
Growth - Existing Business CFO, VP of BD, and the resourcing & reorganising of the R&D Build Capability (people) and Product Teams to expedite product development pipeline For personal use only Product Improvements FerriScan scan time reduction, Cardiac T2* 3T, and others New Products Liver Fibrosis
Slide 7: Clinical Trial Opportunity
Clinical Trial Opportunity This opportunity is underpinned by the over-arching strategy of leveraging clinical trial relationships to gain a greater share of spending within the clinical trial ecosystem. For personal use only Other Services Existing Products Imaging, Lab, Biobanks, Australian FerriS
Slide 8: Clinical Trial Value Drivers
Clinical Trial Value Drivers Clinical trials are characterised by more complex requirements resulting in premium prices. For personal use only Clinical Trials 8% Phantoms 8% Diagnostic 92% Clinical Trials 34% Diagnostic 58% CASES FY23 REVENUE FY23 8
Slide 9: Clinical Trials in Australia
Clinical Trials in Australia Australia is a highly attractive clinical trial destination – In 2019 95,000 people participated in over 1,800 trials, a 7% CAGR in trials since 2015. Industry sponsored trials were worth >$1.12B. For personal use only Benefits ü Approvals and regulatory system. ü Public
Slide 10: Growth Opportunities
Growth Opportunities MRI Liver Fibrosis / Inflammation Measurement For personal use only § Extended proof of concept underway. Results early next calendar year pave the way to partner with global Pharma to use product for investigational purposes in a trial. Both monetizing and moving towards regula
Slide 11: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Resonance Health Ltd (“Resonance Health” or “Company”) and may contain forward-looking statements that are based on current expectations and beliefs and are subject to numerous factors and uncertainties that could cause actual r
Resonance Health — Shareholder Meeting (November 2023) on 6ix